ArticleBMC gastroenterology2025
Neoadjuvant combination immunotherapy for colorectal cancer: clinical and molecular predictors of pathological complete response and safety assessment.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo identify the clinical and molecular factors that effectively predict pathological complete response (pCR) and assess the safety of patients receiving neoadjuvant combination immunotherapy.
methodsThis retrospective study evaluated 81 patients with colorectal cancer (CRC) at a Chinese tertiary center between 2015 and 2023. The cohort included 24 patients with deficient mismatch repair (dMMR) and 57 patients with proficient mismatch repair (pMMR) tumors. Patients were treated with a neoadjuvant combination of immunotherapy and surgery.
resultsWe divided 81 patients into pCR (40.7%) and non-pCR (59.3%) groups. The factors significantly associated with a higher pCR rate after neoadjuvant combination immunotherapy were younger age, low carcinoembryonic antigen (CEA) level, high tumor mutational burden (TMB) level before treatment, clinical stage III, absence of lymph node metastasis before treatment, MSI-H level, dMMR, and pole status mutation. Preoperative combined chemotherapy and targeted therapy also influenced the pCR rate. Neoadjuvant combination immunotherapy showed an overall adverse event (AE) rate of 29.6%, with none of grades 3‒4. Surgery-related adverse reactions (srAEs) were also absent for grades 3‒4; 14 of the 81 patients experienced grade 1‒2 AEs.
conclusionNeoadjuvant combination immunotherapy resulted in a favorable pCR rate in patients with CRC. Young age, pretreatment CEA level, TMB level, clinical stage, lymph node metastasis, MSI, MMR, and pole status can be used as indicators of the efficacy of neoadjuvant combination immunotherapy. The incidence of AEs from neoadjuvant combination immunotherapy and surgery was low, indicating that this regimen is safe and feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.